Key Highlights The peer-reviewed study, published in Pharmaceutics (MDPI), describes the non-clinical safety pharmacology, toxicokinetics and pharmacodynamics of VMX-C001 in...
Adopted USAN: Reltodecacog alfa has been adopted by the United States Adopted Names (USAN) Council as the non-proprietary name for...
Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m...
Designation recognises potential of VMX-C001 to address an unmet need in the restoration of coagulation to enable hemostasis in patients...
Enables initiation of global EquilibriX-S trial later this year Critical milestone in development of novel bypass agent to restore coagulation,...
Most competitive selection process so far since the launch of the Accelerator under Horizon Europe Follow-on funding reflects significant potential...
Leiden, The Netherlands, 10 December 2024 – VarmX, a biotech company developing innovative approaches for the bypass of direct oral...
Oral and poster presentations on key VMX-001 data in San Diego from 7-10 December Leiden, The Netherlands, 3 December 2024...